Hydroxychloroquine. Seven-year experience
D. R. Tobin, G. Krohel and R. I. Rynes
Ninety-nine patients were treated with hydroxychloroquine sulfate for
connective tissue diseases during a seven year period. All patients
received the medication for at least one year and most were treated with a
daily dosage of 400 mg. Four patients experienced toxic effects, but no
patient sustained permanent loss of visual acuity. Toxicity did not seem to
represent a cumulative dosage effect. Funduscopic and visual field
examinations at six-month intervals are sufficient to detect the occasional
adverse reactions and prevent serious retinal toxic effects when a maximum
daily dosage of 400 mg is maintained.
